Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia

Future Oncology

Volumn 11, Issue 12, 2015, Pages 1729-1739

  Bumma, Naresh ^a   Papadantonakis, Nikolaos ^b   Advani, Anjali S ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

acute lymphoblastic leukemia; bispecific antibody; blinatumomab; minimal residual disease; relapse

Indexed keywords

BLINATUMOMAB; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; BRAIN TOXICITY; CANCER DIAGNOSIS; CHILL; CONFUSION; CREATININE CLEARANCE; CYTOKINE RELEASE SYNDROME; DISORIENTATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HUMAN; HYPOTENSION; IN VITRO STUDY; LEUKEMIA RELAPSE; LEUKOPENIA; LIMIT OF DETECTION; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REVIEW; SEIZURE; TREMOR; VOLUME OF DISTRIBUTION; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG SCREENING; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TREATMENT OUTCOME;

ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TREATMENT OUTCOME;

EID: 84931395834     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.84     Document Type: Review

References (52)

1. Siegel R, Ma J, Zou Z, Jernal A. Cancer statistics, 2014. CA Cancer J. Clin. 64(1), 9-29 (2014).
2. Reiter A, Schrappe M, Tiemann M et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood 94(10), 3294-3306 (1999).
3. Bleyer WA, Poplack DG. Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. Semin. Oncol. 12, 131-148 (1985).
4. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354(2), 166-178 (2006).
5. Annino L, Vegna ML, Camera A et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 99(3), 863-871 (2002).
6. Fielding A, Richards SM, Chopra R et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 109(3), 944-950 (2007).
7. Gökbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin. Hematol. 46(1), 64-75 (2009).
8. Patel B, Rai L, Buck G et al. Minimal residual disease is a significant predictor of treatment failure in non T lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. Br. J. Haematol. 148(1), 80-89 (2010).
9. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J. Clin. Oncol. 29(5), 532-543 (2011).
10. De Vries JF, Zwaan CM, DeBie M et al. The novel calicheamicin-conjugated CD22 antibody Inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia 26(2), 255-264 (2011).
11. Kantarjian H, Thomas D, Jorgenson J et al. Inotuzumab ozogamicin, an anti-CD22-calicheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a Phase 2 study. Lancet Oncol. 13(4), 403-411 (2012).
12. Carnahan J, Wang P, Kendall R et al. Epratuzumab, a humanized monoclonal antibody targeting CD22 characterization of in vitro properties. Clin. Cancer. Res. 9(10), s3982-s3990 (2003).
13. Raetz EA, Cairo MS, Borowitz MJ et al. Reinduction chemotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL) in children, adolescents, and young adults: results from Children's Oncology Group (COG) study ADVL04P2. Presented at: American Society of Hematology Meeting 2011. San Diego, California, USA, 10-13 December 2011 (Abstract 573).
14. Advani AS, McDonough S, Coutre S et al. SWOG S0910: a Phase 2 trial of clofarabine/ cytarabine/epratuzumab for relapsed/ refractory acute lymphocytic leukaemia. Br. J. Haematol. 165(4), 504-509 (2014).
15. Advani AS, Gundacker HM, Sala-Tora O et al. Southwest Oncology Group Study S0530: a Phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Br. J. Haematol. 151(5), 430-434 (2010).
16. International Study for the Treatment of Standard Risk Childhood Relapsed ALL 2010. A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group. www.clinicaltrials.gov
17. Fathi A, Chen R, Trippett TM et al. Interim analysis of a Phase 1 study of the antibodydrug conjugate SGN-CD19A in relapsed or refractory B-lineage acute leukemia and highly aggressive lymphoma. Presented at: 56th ASH Annual Meeting and Exposition. San Francisco, CA, USA, 6-9 December 2014 (Abstract 963).
18. Porter DL, Levine BL, Kalos M et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733(2011).
19. Brentjens RA, Davila ML, Riviere I et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5(177), 177ra38 (2013).
20. Grupp SA, Maude S, Shaw P et al. T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019)-have long term persistence and induce durable remissions in children with relapsed, refractory ALL. Presented at: 56th ASH Annual Meeting and Exposition. San Francisco, CA, USA, 6-9 December 2014 (Abstract 380).
21. Jeha S, Gaynon PS, Razzouk BI et al. Phase II study of clofarabine in pediatric patients with relapsed or refractory acute lymphoblastic leukemia. J. Clin. Oncol. 24(12), 1917-1923 (2006).
22. DeAngelo DJ, Yu D, Johnson JL et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 109(12), 5136-5142 (2007).
23. O'Brien S, Thomas D, Cortes J et al. Marqibo® (vincristine sulfate liposomes injection; VSLI) in the treatment of adult patients with advanced, relapsed/refractory acute lymphoblastic leukemia (ALL): a combined analysis of the VSLI-06 and RALLY studies. Presented at: American Society of Hematology (ASH) 52nd Annual Meeting. FL, USA, 4-7 December 2010 (Abstract 2143).
24. Thomas DA, Sarris AH, Cortes J et al. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer 106(1), 120-127 (2006).
25. O'Brien S, Schiller G, Lister J et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosomenegative acute lymphoblastic leukemia. J. Clin. Oncol. 31(6), 676-683 (2013).
26. Barry M, Bleackley RC. Cytotoxic T lymphocytes: all roads lead to death. Nat. Rev. Immunol. 2(6), 401-409 (2002).
27. Maher J, Davies E. Targeting cytotoxic T lymphocytes for cancer immunotherapy. Br. J. Cancer 91(5), 817-821 (2004).
28. Bargou R, Leo E, Zugmaier G et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321(5891), 974-977 (2008).
29. Swartz MA, Hirosue S, Hubbell JA. Engineering approaches to immunotherapy. Sci. Transl. Med. 4(148), 148rv149 (2012).
30. Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk. Lymphoma 18, 385-397 (1995).
31. Loffler A, Kufer P, Lutterbuse R et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95(6), 2098-2103 (2000).
32. Hoffmann P, Hofmeister R, Brischwein K et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int. J. Cancer 115(1), 98-104 (2005).
33. Dreier T, Lorenczewski G, Brandl C et al. Extremely potent, rapid and costimulationindependent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int. J. Cancer 100(6), 690-697 (2002).
34. Nagorsen D, Kufer P, Baeuerle PA et al. Blinatumomab: a historical perspective. Pharmacol. Ther. 136(3), 334-342 (2012).
35. Uckun FM, Jaszcz W, Ambrus JL et al. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 71(1), 13-29 (1988).
36. Wormann B, Anderson JM, Liberty JA et al. Establishment of a leukemic cell model for studying human pre-B to B cell differentiation. J. Immunol. 142(1), 110-117 (1989).
37. Yao R, Rich SA, Schneider E. Validation of sixteen leukemia and lymphoma cell lines as controls for molecular gene rearrangement assays. Clin. Chem. 48(8), 1344-1351 (2002).
38. D'argouges S, Wissing S, Brandl C et al. Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leuk. Res. 33(3), 465-473 (2009).
39. Schlereth B, Quadt C, Dreier T et al. T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol. Immunother. 55(5), 503-514 (2006).
40. Klinger M, Brandl C, Zugmaier G et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/ CD3-bispecific BiTE antibody blinatumomab. Blood 119(26), 6226-6233 (2012).
41. Wong R, Pepper C, Brennan P et al. Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells. Haematologica 98(12), 1930-1938 (2013).
42. Abulayha A, Bredan A, Enshasy HE et al. Rituximab: modes of action, remaining dispute and future perspective. Future Oncol. 10(15), 2481-2492 (2014).
43. Topp MS, Kufer P, Gokbuget N et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol. 29(18), 2493-2498 (2011).
44. Wu B, Hijazi Y, Wolf A et al. Pharmacokinetics (PK) of blinatumomab and its clinical implications. J. Clin. Oncol. 31(15), Abstract 3048 (2013).
45. Brandl C, Haas C, D'argouges S et al. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Cancer Immunol. Immunother. 56(10), 1551-1563 (2007).
46. Teachey DT, Rheingold SR, Maude SL et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121(26), 5154-5157 (2013).
47. Topp M, Gokbuget N, Zugmaier N et al. Long-term follow-up of hematologic relapse-free survival in a Phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120(26), 5185-5187 (2012).
48. von Stackelberg A, Locatelli F, Zugmaier G et al. A Phase 1/2 study in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) receiving blinatumomab treatment. Presented at: 56th ASH Annual Meeting and Exposition. San Francisco, CA, USA, 6-9 December 2014 (Abstract 2292).
49. Topp MS, Gokbuget N, Stein AS et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, Phase 2 study. Lancet Oncol. 16(1), 57-66 (2015).
50. Goekbuget N, Dombret H, Bonifacio M et al. BLAST: a confirmatory, single-arm, Phase 2 study of blinatumomab, a bispecific T-cell engager (BiTE®) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL). Presented at: 56th ASH Annual Meeting and Exposition. San Francisco, CA, USA, 6-9 December 2014 (Abstract 379).
51. Zugmaier G, Topp MS, Alekar S et al. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J. 4, 244 (2014).
52. Topp MS, Gokbuget N, Zugmaier G et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J. Clin. Oncol. 32(36), 4134-4140 (2014).